CD274 and non-small cell lung carcinoma: This study has demonstrated that ICIs in combination with chemotherapy significantly improve the disease control and reduce the risk of disease progression but have no statistically significant survival benefits compared with ICIs alone in the first‐line treatment of PD‐L1 high expression (TPS ≥ 50%) advanced NSCLC.